BSX
Boston Scientific’s pricey side quest
Boston Scientific just wrote a very large check — $1.5 billion, to be exact — in exchange for about a 34% stake in MiRus LLC. That’s not the kind of move you make because you had leftover coffee money; it’s a strategic bet with real skin in the game.
What’s the play here?
This looks less like a standard vendor relationship and more like Boston Scientific getting a front-row seat to whatever MiRus is building. With a minority stake this size, BSX gets exposure without buying the whole company — the corporate equivalent of dating before getting married.
Why investors should care
A deal like this can be a clue about where Boston Scientific sees future growth, especially if MiRus’s tech fits into areas like structural heart or other high-value device categories. If the bet works, BSX could strengthen its pipeline without waiting years to build everything in-house.
- Big check, small control: BSX is investing heavily but isn’t taking full ownership.
- Strategic signal: the company is clearly shopping for more growth lanes.
- Watch the follow-through: the real question is whether this turns into commercial upside or just an expensive science project.
Big picture: Boston Scientific is buying optionality — and paying up for it.